80 results about "Chelating ligands" patented technology

Disclosed are a core-shell quantum dot, a quantum dot light-emitting device, a display apparatus and a manufacturing method. The core-shell quantum dot includes: a core part; a shell layer arranged on at least part of a surface of the core part, and including metal ions; and a chelating ligand connected with the metal ions, where the chelating ligand and the metal ions form a closed ring structure connected with the shell layer.

A nano composite, a nanoparticle ink composition including a solvent and the nanocomposite, and a light-emitting device including a first electrode, a second electrode facing the first electrode, and an interlayer between the first electrode and the second electrode, wherein the interlayer includes an emission layer, and at least one layer included in the interlayer is made from the nanoparticle ink composition. The nano composite includes: a metal oxide nanoparticle; and a chelating ligand bonded to a surface of the nanoparticle and including a cyclic moiety.

Provided is a compound for double targeting of a fibroblast activation protein and an integrin subtype, comprising: (i) a chelating ligand moiety (CL); (ii) a first targeting moiety (BT); and (iii) a second targeting moiety (CY), wherein (i), (ii), and (iii) are fixed, combined, or connected by means of any L; BT is a fibroblast activation protein (FAP)-specific binding ligand structure; CY is an integrin subunit αvβ3 or αvβ6-specific binding ligand structure; L is selected from one or a combination of L1, L2, L3, L4, L5, L6, and L7; L1, L2, L3, L4, L5, L6, and L7 are each independently a key, a monovalent joint, a divalent joint, or a trivalent joint. Also provided are a preparation method for the compound and use thereof.

The invention relates to the technical field of electrocatalysis, in particular to a preparation method and application of a novel bismuth nanocrystal / nitrogen-rich graphite carbon electrocatalyst, and the preparation method comprises the following steps: S1, adding urea and ammonium chloride into water, stirring, freeze-drying and grinding to obtain a chelating ligand; s2, adding bismuth citrate into the chelating ligand, and carrying out solid-phase reaction to obtain a precursor; and S3, calcining the precursor under the protection of nitrogen to obtain the bismuth nanocrystal / nitrogen-rich graphite carbon electrocatalyst. The problems that reduction and reconstruction reactions are likely to happen in the CO2 electrocatalytic reduction catalysis process, and the difficulty of active site recognition and performance regulation and control is increased can be solved.

The invention discloses a Nectin-4 targeted nucleic acid aptamer nuclide diagnosis and treatment integrated probe, and relates to the field of biotechnology and diagnosis and treatment integration and treatment, and the diagnosis and treatment integrated probe comprises a Nectin-4 targeted nucleic acid aptamer, a nuclide chelating ligand and a nuclide for marking; wherein the Nectin-4 targeting nucleic acid aptamer has a base sequence as shown in any one of SEQ ID NO.1-3, or has a base sequence of which the homology with the base sequence as shown in any one of SEQ ID NO.1-3 is more than 80%. The diagnosis and treatment integrated probe prepared by the invention can be applied to PET / CT diagnosis and internal irradiation radioactive therapy, on one hand, non-invasive visual molecular imaging of Nectin-4 receptor protein overexpression tumors is realized, and on the other hand, radioactive therapy of malignant bladder cancer is further realized; the probe is good in specific targeting effect and high in tumor uptake and has a diagnosis and treatment integrated function.

This invention discloses a catalytic cracking co-catalyst with high resistance to thermal abrasion, comprising a molecular sieve, a matrix, a binder, and a binder modifier. The molecular sieve has an MFI structure, and the molecular sieve with a pore diameter less than 0.7 nm accounts for 50 wt% to 100 wt% of the total molecular sieve. The matrix is ​​composed of a γ-alumina precursor with a colloidal index ≤ 50% and clay. The binder is prepared from phosphorus-containing and aluminum-containing compounds. The raw materials for the binder modifier include multi-chelate ligands, precursors of at least two coordination metals, alcohols, and organic acids. The binder, binder modifier, and matrix are all mixed in a high-shear emulsifier. Compared with existing catalytic cracking co-catalysts for propylene and octane number, the catalytic cracking co-catalyst provided by this invention has higher resistance to thermal abrasion, larger pore volume, and higher molecular sieve content.

This invention belongs to the field of food processing technology, specifically providing a method for preparing antioxidant zinc chelate peptides, comprising the following steps: inoculating a protein solution with a compound microbial agent for fermentation; the compound microbial agent includes *Lactobacillus plantarum* and *Saccharomyces cerevisiae*; after enzymatic hydrolysis and debittering of the fermentation broth, the antioxidant peptides are separated and dried to obtain the antioxidant peptides; the antioxidant peptides are dissolved in water to prepare a peptide solution, and a zinc source is added to the peptide solution to carry out a chelation reaction; the supernatant is collected, and the precipitate is collected by alcohol precipitation to obtain the antioxidant zinc chelate peptides. This method uses low molecular weight peptides prepared by dual-microbial synergistic multi-enzyme hydrolysis as chelating ligands, which chelate with zinc ions under mild conditions to maximize the preservation of biological activity, achieving a dual enhancement of chelation capacity and antioxidant activity, and achieving a unity of high chelation rate, high antioxidant activity, high stability and good flavor. The process is green, safe, and leaves no organic solvent residue, making it suitable for large-scale industrial production.

The invention belongs to the technical field of medical materials, and discloses a preparation method and application of a manganese-based micromolecule magnetic resonance imaging contrast agent. According to the invention, a macrocyclic chelating ligand H4L is firstly prepared, then the manganese-based micromolecular complex MnL2-is prepared by using the ligand, the molecular formula of the manganese-based micromolecular complex MnL2-is C38H56MnN10O92-, and the manganese-based micromolecular complex MnL2-can be used as a magnetic resonance imaging contrast agent. Through detection, the product has very good stability, and the hydration condition q of the complex is equal to 0.78 through 17O NMR (nuclear magnetic resonance) test and relaxation rate test, which indicates that the complex has one coordination water and can provide a monitorable magnetic resonance signal. And the obtained relaxation rate r1 is equal to 2.255 mM <-1 > s <-1 >, which shows that the product has great application value.

The present application relates to a cage-like chelate, a targeted cage-like chelating ligand, and a complex and the use thereof. Provided in the present application is a cage-like chelate, which has a skeleton structure with more diverse modifiable sites and a higher flexibility, and has broad-spectrum adaptability. The cage-like chelate and the targeted cage-like ligand formed thereby can form a compound with a higher targeting ability and stability after complexation with a nuclide, thereby mitigating the daughter nuclide recoil effect of alpha nuclide-labeled drugs in organisms, and reducing toxic and side effects of alpha decay on normal tissues.

The invention discloses a Zr-doped nickel-based electrocatalyst based on a 4, 4 '-dipyridyl chelating ligand and a preparation method and application thereof.The Zr-doped nickel-based electrocatalyst is characterized in that Ni < 2 + > serves as a central metal ion, 4, 4'-dipyridyl serves as the chelating ligand, and a stable coordination structure is constructed; zr is introduced as a doping element, and the electron density and the coordination environment of the catalyst are regulated and controlled by adjusting the doping proportion of Zr; and carbon fiber paper is used as a load electrode. A supported catalyst is prepared by using a constant-current electrodeposition method under a three-electrode system, and the catalyst is directly deposited on the surface of carbon fiber paper to form a self-supporting structure. The preparation method is simple in process, can be amplified on a large scale, and does not need a high-temperature roasting or complex solvent heat treatment step. The obtained catalyst is used for preparing adipic acid by electrocatalytic oxidation of cyclohexanol under an alkaline condition, and shows excellent catalytic activity and selectivity. The invention provides a green, efficient and low-cost adipic acid electrocatalytic synthesized novel electrocatalytic material, and the novel electrocatalytic material has a good industrial application prospect.

Compositions and methods for the removal and prevention of scale in pulp mills in a continuous and real-time process. More particularly the composition includes one or more chelating ligands, one or more copolymers, and one or more surfactants. The scale removing composition is added to the black liquor stream in pulp and paper processes to remove scaling, such as scaling from calcium carbonate, from surfaces in contact with the black liquor stream, such as in digestors and evaporators.

A tin catalyst for polyurethane synthesis has a structure according to the following formula (I): SnX1 n1X2 n2(L1)n3(L2)n4 whereby: each X1 and each X2 independently of each other stands for an anionic ligand, in particular a monovalent anionic ligand, especially selected from halides, hydroxides, oxygen, sulfur, alcoholates, thiolates and / or carboxylates, optionally with a saturated or unsaturated, cyclic or acyclic, branched or unbranched, substituted or unsubstituted hydrocarbon residue, whereby the hydrocarbon residues may be interrupted by heteroatoms; n1 and n2 independently of each other is 0, 1 or 2; especially the sum of n1 and n2 is 0, 1 or 2; each L1 and each L2 independently of each other stand for a polydentate chelating ligand having form 6 – 50 carbon atoms, and at least one phenoxy group forming a covalent Sn-O bond, especially 2, 3 or 4 phenoxy groups each forming a covalent Sn-O bond; at least one amine and / or imine group, in particular forming a coordination bond with Sn, especially 2 amine and / or imine group each forming a coordination bond with Sn; n3 is 1 or 2 and n4 is 0, 1 or 2; and whereby X1, X2, L1 and L2 are chemically different from each other.

This invention relates to the field of chelating drug research, specifically to chelating ligand compounds, targeted chelating ligands and their complexes and applications. Compared with the prior art, the targeted molecule linking sites and linking methods disclosed in this invention have better targeting and in vivo stability. At the same time, the design of the targeted molecule linking sites in this invention can improve in vivo metabolism and distribution, thereby improving the druggability of preferred compounds and providing a better foundation for the clinical application of therapeutic radiopharmaceuticals.

The invention discloses a perovskite solar cell based on a multi-site chelate ligand and a preparation method thereof. The cell comprises an ITO conductive glass layer, a hole transport layer, a perovskite photoactive layer, a passivation layer, an electron transport layer and a metal electrode from bottom to top. The method is characterized in that a polydentate chelating ligand N, N '-ethylenediamine disuccinic acid (EDDS) is doped in a perovskite photoactive layer, and the ligand and uncoordinated Pb and Idefects on the surface of perovskite form stable coordinate bonds simultaneously through a plurality of carboxyl groups in molecules of the ligand, so that multi-site synergistic passivation is realized, and non-radiative recombination is effectively inhibited. The process is simple and is compatible with the existing spin coating process. The maximum power conversion efficiency of the obtained device can reach 24.57%, the initial efficiency of 90.2% can still be kept after continuous illumination for 3000 hours, and the device has high efficiency and high stability and is wide in application prospect.

The application belongs to the technical field of medical detection, and particularly relates to a polysaccharide contrast agent capable of renal metabolism and a preparation method thereof. The polysaccharide contrast agent has a structure as shown in formula (I), a particle size less than or equal to 8 nm, and can be rapidly metabolized through the kidney. The preparation method is to graft a metal macrocyclic ligand to a nano-crosslinked polysaccharide particle, and to prepare through a deprotection and metal ion chelation step. Since the contrast agent has the characteristic of renal metabolism, phagocytosis of the reticuloendothelial system is reduced, in vivo deposition of the contrast agent is reduced, and thus the biological safety is improved. Since a macrocyclic chelating ligand is used, good kinetic stability is achieved, the risk of in vivo metal ion deposition is reduced, and when applied to in vivo imaging, clear imaging of cardiovascular, lymph node, liver and other parts can be achieved. The preparation method is simple and easy to implement, reaction conditions are mild, is conducive to large-scale production and clinical transformation, and has a wide biomedical application prospect.

Provided is a new composition of matter for phosphorescent emitters containing a chelating ligand comprised of a fused heterocyclic structure containing boron. The disclosed ligands form two bonds to the metal forming a 6-membered chelate and can be further substituted to form tridentate or tetradentate ligands.

This invention provides a binder for a catalytic cracking catalyst and its preparation method. The binder comprises a binder, a curing agent, and a modifier. The curing agent is prepared by a hydrothermal reaction of a γ-alumina precursor, an acid, and an alkylammonium salt. The modifier is prepared by reacting a multi-metal chelate ligand, a metal central ligand, ethanol, and an organic acid. The binder comprises a phosphorus-containing compound and an aluminum-containing compound. In the binder for the catalytic cracking catalyst provided by this invention, a multi-metal chelate modifier composed of a multi-metal chelate ligand and multiple metals is introduced. Under the promotion of organic acid and ethanol, a multi-metal chelate modifier can be prepared in situ during the binder preparation process. Compared with directly using commercially available metal chelates, the in-situ prepared multi-metal chelate modifier has better water solubility and can promote the binding of the modifier with the phosphorus-aluminum sol, resulting in a better modification effect.

The invention provides an analysis method for measuring negative ions in urine based on gas phase ion chromatography, and belongs to the technical field of urine analysis. One of the urine analysis methods based on gas phase ion chromatography can comprise the following steps: injecting a chelating ligand into an analyzer through a continuous sample injector electrospray to obtain a background signal; a to-be-detected urine sample is fed one by one through an online six-way valve automatic sampler, a chelating ligand solution and the urine sample can be fully mixed through an online mixer, electrospray ionization is realized, the mixture enters an analyzer, an ion chromatograph records a sample signal, and a background is deducted to obtain a urine analysis result; wherein the ionization technology is an electrospray ion source. According to the method disclosed by the invention, separation of various ions on the gas phase ion chromatography can be realized; the kit can also be used for qualitatively and quantitatively detecting trace inflammatory factors, trace proteins and other proteins in urine, and can be applied to prevention and treatment of kidney stone.

The application relates to the technical field of electrocatalysis, in particular to a preparation method and application of a bismuth nanocrystal / nitrogen-rich graphite carbon electrocatalyst, which comprises the following steps: S1, adding urea and ammonium chloride into water, stirring, freeze-drying, grinding, and obtaining a chelating ligand; S2, adding bismuth citrate into the chelating ligand, carrying out a solid-phase reaction, and obtaining a precursor; and S3, calcining the precursor under nitrogen protection, and obtaining the bismuth nanocrystal / nitrogen-rich graphite carbon electrocatalyst. The problems that reduction and reconstruction reactions are prone to occur in the process of catalyzing CO2 electrocatalytic reduction, and the difficulty in increasing the recognition and performance regulation of active sites can be solved.

A method for preparing glutaryl-bridged bis-biogenic guanidine chelate (GbG)MX2 including contacting biogenic guanidine (G) with glutaryl chloride in DMSO solvent for an acylation reaction, to yield glutaryl-bridged bis-biogenic guanidine GbG (G-b-G), and mixing the glutaryl-bridged bis-biogenic guanidine GbG as a chelating ligand and a non-toxic metal salt MX2 in an amphiphilic mixed solvent DMSO-H2O for a ligand addition reaction, to yield glutaryl-bridged bis-biogenic guanidine chelate (GbG)MX2. The biogenic guanidine (G) is selected from arginine (Arg), guanidine acetic acid (Gaa), creatine (Cra), and creatinine (Cran). M represents Fe2+, Mg2+, or Zn2+; and X represents CI−, AcO−(CH3COO−), LaO−(CH3CH(OH)COO−). The glutaryl-bridged bis-biogenic guanidine chelate (GbG)MX2 can be used as a catalyst for production of polybutylene succinate (PBS) using succinic anhydride (SAn) and BDO as monomers through a batch process or a continuous process. The catalyst of (GbG)MX2 of the disclosure is non-toxic, and the PBS synthesized features excellent environmental and biological safety.

A tin catalyst for polyurethane synthesis has a structure according to the following formula (I):         SnX1n1X2n2(L1)n3(L2)n4     (I) whereby: each X1 and each X2 independently of each other stands for an anionic ligand, in particular a monovalent anionic ligand, especially selected from halides, hydroxides, oxygen, sulfur, alcoholates, thiolates and / or carboxylates, optionally with a saturated or unsaturated, cyclic or acyclic, branched or unbranched, substituted or unsubstituted hydrocarbon residue, whereby the hydrocarbon residues may be interrupted by heteroatoms; n 1 and n2 independently of each other is 0, 1 or 2; especially the sum of n 1 and n2 is 0, 1 or 2; each L1 and each L2 independently of each other stand for a polydentate chelating ligand having form 6-50 carbon atoms, and at least one phenoxy group forming a covalent Sn-O bond, especially 2, 3 or 4 phenoxy groups each forming a covalent Sn-O bond; at least one amine and / or imine group, in particular forming a coordination bond with Sn, especially 2 amine and / or imine group each forming a coordination bond with Sn; n3 is 1 or 2 and n4 is 0, 1 or 2; and whereby X1, X2, L1 and L2 are chemically different from each other.

The invention discloses a preparation method and application of a semi-sandwich type iridium complex containing a tridentate ligand. The structural formula of the complex is shown as a formula (I), a ligand and a dimer react under the reaction condition, sodium bicarbonate is continuously added into a reaction system, proton H on coumarin unit carbon in the ligand can be selectively removed, and therefore the semi-sandwich type iridium complex (I) of the CNS tridentate ligand is obtained. Wherein a coordination carbon atom (C, blue) in the tridentate chelate ligand is derived from a coumarin unit, a nitrogen atom (N, red) is derived from a Schiff base structure, a sulfur atom (S, pink) is derived from thiosemicarbazide, the obtained iridium complex shows good anticancer activity, the performance of the iridium complex is close to or even superior to that of commercial cis-platinum, and the iridium complex is a very potential anticancer drug.

The invention belongs to the technical field of medical detection, and particularly relates to a polysaccharide contrast agent capable of realizing kidney metabolism and a preparation method thereof. The polysaccharide contrast agent has a structure as shown in a formula (I), the particle size is smaller than or equal to 8 nm, and the polysaccharide contrast agent can be rapidly metabolized through the kidney. The preparation method comprises the following steps: grafting a metal macrocyclic ligand to nano cross-linked polysaccharide particles, and carrying out deprotection and metal ion chelation to prepare the nano cross-linked polysaccharide. The contrast agent has the characteristic of kidney metabolism, so that the phagocytosis of a reticuloendothelial system is reduced, the in-vivo deposition of the contrast agent is reduced, and the biological safety is improved. Due to the use of the macrocyclic chelating ligand, good dynamic stability is achieved, the risk of in-vivo metal ion deposition is reduced, and clear imaging can be conducted on cardiovascular, lymph nodes, livers and other parts when the compound is applied to in-vivo imaging. The preparation method disclosed by the invention is simple and easy to implement, mild in reaction condition and beneficial to large-scale production and clinical conversion, and has a wide biomedical application prospect.

The present invention relates to a complex of formula (II) consisting of at least 90% of a diastereomeric excess comprising a mixture of II-RRR and II-SSS isomers of formulas: (see Formulas) (II-SSS) (II-RRR) The present invention also relates to a process for the preparation and purification of said complex of formula (II), as well as a composition comprising said complex.

The present invention discloses a bimetallic synergistic catalytic system containing a chelating ligand and its application in the asymmetric synthesis of bedaquiline. Specifically, in the bimetallic synergistic catalytic system, a chelating ligand formed by a non-chiral secondary amine and lithium chiral amino alcohol increases the equilibrium constant of the reaction, promoting the addition reaction of 6-bromo-3-benzyl-2-methoxyquinoline (I) and 3-dimethylamino-1-naphthalen-1-yl-propan-1-one (II) to proceed in the forward direction, and this bimetallic synergistic catalytic system significantly improves the yield of the target product (1R,2S)-bedaquiline.

A process may involve treating calcium sulfate separated from phosphoric acid with acid to obtain a suspension comprising purified calcium sulfate, separating the purified calcium sulfate in solid form from a liquid phase of the suspension, treating the purified calcium sulfate with water or with a salt- and / or chelate ligand-containing aqueous solution to leach rare earths out of the calcium sulfate, separating the further-purified calcium sulfate in solid form from the liquid phase of the suspension, mixing the purified calcium sulfate that is separated off with admixtures and reducing agents to obtain a raw meal mixture for cement clinker production, burning the raw meal mixture to obtain the cement clinker and thereby forming sulfur dioxide as offgas, and feeding the sulfur dioxide as raw material to sulfuric acid production to produce the sulfuric acid.

This invention relates to the application of compound A and its derivatives in the preparation of radiopharmaceuticals. The inventors discovered that compound A forms a chelated ligand compound with a target molecule via a linker, which then interacts with the radionuclide. 9 Zr、 47 Sc、 55 Co、 60 Cu、 61 Cu、 62 Cu、 64 Cu、 67 Cu、 66 Ga、 67 Ga、 68 Ga、 82 Rb、 86 Y、 87 Y、 90 Y、 97 Ru、 105 Rh、 109 Pd, 111 In、 117m Sn、 149 Pm, 52 Mn, 149 Tb, 152 Tb, 161 Tb, 99m Tc, 153 Sm、 177 Lu、 186 Re、 188 Re、 199 Au、 201 Tl、 203 Pb, 210 Pb, 212 Pb, 212 Bi、 213 Bi、 225 Ac、 223 Ra and 227 Th can form stable chelates labeled with radioactive metal nuclides under conditions without heating or low temperature. This chelation reaction is highly efficient, and the purity of the chelated product is greater than 95%. Furthermore, the resulting nuclide chelate derivatives exhibit low toxicity and good metabolic properties in vivo, indicating high clinical pharmaceutical potential.

The invention relates to a method for producing a MOF, wherein a MOF is a structured metal-organic compound comprising a bi- or tri-dimensional porous network consisting of inorganic entities that are connected by polydentate chelating ligands bonded to multiple metal centers; the polydentate chelating ligands being selected in particular from the group comprising C5-C24 heteroaromatic ligands and aromatic ligands, comprising at least one carboxylic acid function, preferably benzyl or naphthyl di-, tri- or tetracarboxylate, and the aromatic or heteroaromatic ligands optionally bearing, on at least one aromatic ring, a group selected from among —NH2, —OH, —CH3, —NO2, —CF3, —COOH, —SO3H, —SH, —OCH3.

The invention provides a CAIX ligand compound, a metal complex and application of the CAIX ligand compound and the metal complex, the structure of the compound is shown as a formula (A), and in the formula (A), R1 is selected from hydrogen or-L1-E1; r < 2 >, R < 3 >, R < 4 >, R < 5 >, R < 6 > and R < 7 > are independently selected from hydrogen or-L2-E2; each of the E1 and the E2 is independently a chelating ligand moiety; l1 and L2 are respectively and independently composed of a plurality of amino acid residues L; the basic fragment L0 of the amino acid residue L is selected from at least one of-Z-,-N (R8)-,-N (R8) 4,-C (= Z)-,-((C (R9) p) q-,-SO3H,-S (= O) j-,-NR8-C (= O)-,-NR8-C (= O)-NR8-,-C (= O)-NR8-,-((C (R9) p) q-Z) x-(C (R9) p) q-,-(C (R9) p) q-(Z-(C (R9) p) q) x-, alkylene, heteroalkylene, cycloalkylene, heterocyclic alkylene, arylene or heteroarylene; under a reasonable condition, a plurality of L0 are mutually spliced to form L, and one or more L can be mutually combined to form L1 or L2; or one or more L0 can be combined with each other to form L1 or L2. The compound provided by the invention can effectively optimize in-vivo pharmacokinetic characteristics and tumor retention capacity, and is used for developing and treating ccRCC.